FOR IMMEDIATE PRESS RELEASE

*** The final dates and preliminary agenda for the 4th World Conference on Congenital Disorders of Glycosylation (CDG) for Families and Professionals “The CDG road: from diagnosis to therapies”

Lisbon, 27th November 2018 – After consulting with the CDG Community, the final dates for the 4th World Conference on Congenital Disorders of Glycosylation (CDG) for Families and Professionals “The CDG road: from diagnosis to therapies” are out!

We are very excited to receive you in Lisbon on the 26th and 27th of July 2019 for this unique international event for the CDG Community that joins families and professionals.

The preliminary agenda is also available and for next year’s conference we have focused on the several steps that lead to therapies: diagnosis, pre-clinical research, clinical trials and management therapies that are already available for the CDG Community.

This is a diverse agenda which intends to bring together all the important stakeholders: Patients and Families, Researchers and Medical professionals and Pharmaceutical companies. Aligned with our Patient-Centric approach we will also organize the 1st World Meeting for CDG Patient Groups.

All the information is available at the 4th World Conference on CDG website: http://www.apcdg.com/events.html

In the name of the Portuguese CDG and Other Metabolic Rare Disorders Association (APCDG) we welcome all the CDG Community to participate in the 4th World Conference on Congenital Disorders of Glycosylation (CDG) for Families and Professionals “The CDG road: from diagnosis to therapies”!
About the Portuguese CDG and Other Metabolic Rare Disorders Association (APCDG):

Founded in 2010, APCDG (www.apcdg.com) is a patient led and centric non-profit association, whose particular goal is to stimulate new research lines that make a difference in the lives of patients and families. APCDG initiatives are developed both nationally and internationally. APCDG is committed to finding a cure for Congenital Disorders of Glycosylation (CDG) and related disorders, to improving the treatment options and to giving information and support to people with CDG, through research, education, awareness programs and advocacy. APCDG top priority is to give a complete and holistic perspective of the patient as a person. Go to our website: www.apcdg.com

About CDG & Allies-PPAIN: With the help of a broad network of scientists, physicians, families and patient advocacy groups, we have established a patient-led national and internationally unrivaled infrastructure for research, awareness and education for CDG. The research on glycosylation disorders is primarily dedicated to Congenital Disorders of Glycosylation (CDG). The advances and innovations achieved for CDG through CDG & Allies - PPAIN will impact on a large number of patients, namely all human diseases characterized by abnormal protein glycosylation such as cancer, inflammation, Alzheimer disease and diabetes.

Contact: Sandra Brasil, PhD, Researcher and Patient Advocate at APCDG (more information HERE). Email: s.arduim@gmail.com